JP6200437B2 - Ｔｏｓｏ活性を調節するための方法および組成物 - Google Patents

Ｔｏｓｏ活性を調節するための方法および組成物 Download PDF

Info

Publication number
JP6200437B2
JP6200437B2 JP2014561543A JP2014561543A JP6200437B2 JP 6200437 B2 JP6200437 B2 JP 6200437B2 JP 2014561543 A JP2014561543 A JP 2014561543A JP 2014561543 A JP2014561543 A JP 2014561543A JP 6200437 B2 JP6200437 B2 JP 6200437B2
Authority
JP
Japan
Prior art keywords
toso
protein
antibody
mice
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014561543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511599A5 (enExample
JP2015511599A (ja
Inventor
トゥッシェ，マイケル，ダブリュー．
マーク，ターク，ダブリュー．
オハシ，パメラ，エス．
ラング，フィリップ
ラング，カール
ブレナー，ダーク
リン，グロリア
Original Assignee
ユニバーシティ ヘルス ネットワーク
ユニバーシティ ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ ヘルス ネットワーク, ユニバーシティ ヘルス ネットワーク filed Critical ユニバーシティ ヘルス ネットワーク
Publication of JP2015511599A publication Critical patent/JP2015511599A/ja
Publication of JP2015511599A5 publication Critical patent/JP2015511599A5/ja
Application granted granted Critical
Publication of JP6200437B2 publication Critical patent/JP6200437B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
JP2014561543A 2012-03-16 2013-03-14 Ｔｏｓｏ活性を調節するための方法および組成物 Expired - Fee Related JP6200437B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261612183P 2012-03-16 2012-03-16
US61/612,183 2012-03-16
US201261646143P 2012-05-11 2012-05-11
US61/646,143 2012-05-11
US201261731428P 2012-11-29 2012-11-29
US61/731,428 2012-11-29
PCT/IB2013/001179 WO2013136193A2 (en) 2012-03-16 2013-03-14 Methods and compositions for modulating toso activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017162409A Division JP6462800B2 (ja) 2012-03-16 2017-08-25 Ｔｏｓｏ活性を調節するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2015511599A JP2015511599A (ja) 2015-04-20
JP2015511599A5 JP2015511599A5 (enExample) 2016-04-21
JP6200437B2 true JP6200437B2 (ja) 2017-09-20

Family

ID=48747619

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014561543A Expired - Fee Related JP6200437B2 (ja) 2012-03-16 2013-03-14 Ｔｏｓｏ活性を調節するための方法および組成物
JP2017162409A Expired - Fee Related JP6462800B2 (ja) 2012-03-16 2017-08-25 Ｔｏｓｏ活性を調節するための方法および組成物
JP2018244907A Expired - Fee Related JP6744391B2 (ja) 2012-03-16 2018-12-27 Ｔｏｓｏ活性を調節するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017162409A Expired - Fee Related JP6462800B2 (ja) 2012-03-16 2017-08-25 Ｔｏｓｏ活性を調節するための方法および組成物
JP2018244907A Expired - Fee Related JP6744391B2 (ja) 2012-03-16 2018-12-27 Ｔｏｓｏ活性を調節するための方法および組成物

Country Status (9)

Country Link
US (5) US9228006B2 (enExample)
EP (2) EP3626254A1 (enExample)
JP (3) JP6200437B2 (enExample)
KR (1) KR102143887B1 (enExample)
CN (1) CN104394880B (enExample)
AU (3) AU2013234046B2 (enExample)
CA (1) CA2867444C (enExample)
IL (1) IL234683B (enExample)
WO (1) WO2013136193A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018027951A (ja) * 2012-03-16 2018-02-22 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493561B2 (en) 2013-07-03 2016-11-15 University Health Network Antibodies to Toso
KR102188437B1 (ko) 2014-01-15 2020-12-08 메디뮨 엘엘씨 Rsv 특이적 항체 및 이의 기능적 부위
US20150252434A1 (en) * 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
EP3009841A1 (en) * 2014-10-14 2016-04-20 Bernhard-Nocht-Institut für Tropenmedizin Detection of IgM Antibodies using an immune complex (IC) ELISA
BR112017023646A2 (pt) 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
ES2690420T3 (es) * 2015-05-28 2018-11-20 Universität Zu Köln Receptor de antígeno quimérico anti-toso y su uso
SG11202107663UA (en) 2019-01-18 2021-08-30 Univ Health Network Lilrb3-binding molecules and uses therefor
TWI857009B (zh) * 2019-02-15 2024-10-01 大學健康網絡 Ｆｃｍｒ結合分子及其用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3546807C2 (enExample) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2065414C (en) 1989-09-15 2007-05-15 Tse-Wen Chang Treatment of autoimmune disease
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69232859T2 (de) 1991-09-13 2003-04-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
EP0641353A4 (en) * 1991-11-18 1997-07-02 Tanox Biosystems Inc ANTISENSE OLIGONUCLEOTIDES FOR ISOTYPE-SPECIFIC SUPPRESSION OF IMMUNOGLOBULIN PRODUCTION.
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
US6727350B2 (en) * 1997-11-17 2004-04-27 The Board Of Trustees Of The Leland Stanford Junior University Toso
US6555314B1 (en) * 1998-03-30 2003-04-29 Rigel Pharmaceuticals, Inc. Toso as a target for drug screening
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6683168B1 (en) 1998-04-21 2004-01-27 Boston Medical Center Corporation Genes and methods that modulate apoptosis
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
DE69938054T2 (de) 1998-11-18 2009-02-12 Genentech, Inc., South San Francisco Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
HK1042648A1 (zh) 1999-04-14 2002-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, C/O National Institutes Of Health, Office Of Technology Transfer 用於诱导对移植物的免疫耐受的含有免疫毒素和抑制树突细胞成熟的试剂的组合物
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1259595B1 (en) * 2000-02-25 2007-04-04 Immunex Corporation Integrin antagonists
EP2298789B1 (en) 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
WO2002030954A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1576137A4 (en) * 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
EP2298889A1 (en) 2004-12-30 2011-03-23 Agency for Science, Technology and Research Chinese hamster apoptosis-related genes
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
US20100093082A1 (en) 2006-09-08 2010-04-15 Ambrx, Inc. Site Specific Incorporation of Non-Natural Amino Acids by Vertebrate Cells
DK2170938T3 (da) * 2007-06-06 2012-07-16 Res Dev Foundation RTEF-1-varianter samt deres anvendelse til inhibering af angiogenese
PT2291657T (pt) 2008-05-01 2016-07-08 Zymogenetics Inc Níveis séricos de heterotrímeros blys/april e utilização em métodos de diagnóstico
AU2010284428B2 (en) 2009-08-17 2014-09-11 The Penn State Research Foundation Use of NKG2D inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
US9228006B2 (en) 2012-03-16 2016-01-05 University Health Network Methods and compositions for modulating Toso activity
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018027951A (ja) * 2012-03-16 2018-02-22 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物

Also Published As

Publication number Publication date
US9321824B2 (en) 2016-04-26
JP6462800B2 (ja) 2019-01-30
US20150197551A1 (en) 2015-07-16
US9624289B2 (en) 2017-04-18
US20150139995A1 (en) 2015-05-21
KR102143887B1 (ko) 2020-08-12
AU2017272172A1 (en) 2017-12-21
US20180016320A1 (en) 2018-01-18
US20130281356A1 (en) 2013-10-24
AU2019204594A1 (en) 2019-07-18
WO2013136193A8 (en) 2014-05-08
US10822388B2 (en) 2020-11-03
AU2017272172B2 (en) 2019-04-04
EP2825191B1 (en) 2019-08-28
EP3626254A1 (en) 2020-03-25
JP2015511599A (ja) 2015-04-20
US20150299292A1 (en) 2015-10-22
CA2867444A1 (en) 2013-09-19
CN104394880B (zh) 2020-08-28
JP2019054821A (ja) 2019-04-11
EP2825191A2 (en) 2015-01-21
AU2019204594B2 (en) 2021-05-06
AU2013234046B2 (en) 2017-09-07
CA2867444C (en) 2021-04-13
WO2013136193A3 (en) 2014-01-16
US9670265B2 (en) 2017-06-06
AU2013234046A1 (en) 2014-10-09
IL234683A0 (en) 2014-11-30
JP6744391B2 (ja) 2020-08-19
JP2018027951A (ja) 2018-02-22
IL234683B (en) 2020-02-27
KR20150003197A (ko) 2015-01-08
US9228006B2 (en) 2016-01-05
WO2013136193A2 (en) 2013-09-19
CN104394880A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
JP6462800B2 (ja) Ｔｏｓｏ活性を調節するための方法および組成物
JP6538707B2 (ja) 免疫応答を調節するための方法及び組成物
KR101692080B1 (ko) 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
TWI304811B (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
RU2426742C2 (ru) Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
JP2022512778A (ja) 抗－ｃｄ４５抗体及びそのコンジュゲート
EA015009B1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
CN1938045A (zh) 治疗自身免疫和炎性疾病以及器官移植排异的拮抗性抗－cd40抗体的应用
WO2010022175A1 (en) Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160229

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170825

R150 Certificate of patent or registration of utility model

Ref document number: 6200437

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees